---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-070448"
form_type: "8-K"
ticker: "MGX"
cik: "0001785279"
company_name: "Metagenomi Therapeutics, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T17:03:08.388476+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Metagenomi NHP hemophilia A study shows durable FVIII activity through 19 months; Q1 cash $226M

## Summary
- Hemophilia A NHP study: durable FVIII activity at therapeutically relevant levels through ~19 months; final FVIII levels 80%, 10%, 32%.
- Cash, equivalents, and marketable securities $226.0M as of Mar 31, 2025; runway into 2027.
- R&D expenses $25.1M (Q1 2025) vs $31.4M (Q1 2024); G&A $6.8M vs $8.8M.
- Published novel compact CRISPR-associated transposases in Nature Communications.

## SEC filing metadata
- accession: 0000950170-25-070448
- form_type: 8-K
- ticker: MGX
- cik: 0001785279
- company_name: Metagenomi Therapeutics, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785279/000095017025070448/0000950170-25-070448-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785279/000095017025070448/mgx-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-070448
- JSON: https://secwatch.observer/filing/0000950170-25-070448.json
- Plain text: https://secwatch.observer/filing/0000950170-25-070448.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.